



Kala's Ocular Disease Program Selected as a Top 10 Project to Watch

Waltham, Mass., November 13, 2013 – Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that its dry eye disease program has been chosen as one of the Top 10 Anti-inflammatory/Autoimmune Projects to Watch by Elsevier Business Intelligence. Guillaume Pfefer, Ph.D., Kala's President and Chief Executive Officer, will provide a summary of Kala's ocular disease programs, during his presentation at the 2013 Therapeutic Area Partnerships conference being held November 18-20, 2013 at the Hyatt Regency, Boston. Dr. Pfefer's presentation will take place at 11:10 a.m. ET on Tuesday, November 19, 2013 during the Top 10 Anti-Inflammatory/Autoimmune Projects to Watch session.

"We are delighted that our dry eye disease program has been selected as a Top 10 Project to Watch," said Guillaume Pfefer, Ph.D., CEO of Kala. "We have made significant progress advancing a pipeline of ocular disease programs designed to address significant unmet needs based on Kala's proprietary mucus penetrating particle technology. Our pipeline includes product candidates in development for both front and back of the eye disease, including post-surgical ocular inflammation and pain, dry eye, blepharitis, retinal disease and wet age-related macular degeneration."

The Top Projects to Watch were chosen in each of six therapeutic areas by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. The criteria for selection include large market, large unmet medical need, increasing opportunity, history of the molecule/drug, strong science, strong company, diversity of indications, potential for new opportunities beyond initial indications and potential for multi-level partnering opportunities (biotech to biotech and biotech to pharma).

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. is advancing innovative treatments for ocular diseases addressing significant unmet needs in both front and back of the eye based on the Company's proprietary Mucus Penetrating Particle (MPP) technology. Kala's topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Kala's product development pipeline includes: a 1% formulation of loteprednol etabonate (1% LE-MPP) to treat post-surgical ocular inflammation and pain, expected to enter a pivotal clinical study in 2014; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, expected to enter clinical trials in 2014, and a topically applied receptor tyrosine kinase inhibitor (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD), which is advancing toward selection of a clinical candidate in 2014.

Kala's approach to penetrating mucus layers also has potential application in other disease areas, such as respiratory, female reproductive tract, and gastrointestinal diseases, and in these areas the Company will seek partners to out-license its breakthrough technology. Kala was founded by leaders in the fields of nanomedicine and biopharmaceutical engineering, maintains an esteemed group of advisors including co-founder and MIT professor Dr. Robert Langer, and is backed by leading investors including Lux Capital, Polaris Venture Partners, Third Rock Ventures, and Crown Venture Fund, LLC. For more information, please visit www.kalarx.com.

Contact:

Charlie McDermott

Kala Pharmaceuticals, Inc.

Tel: 781 810 4756

info@kalarx.com

Media:

Gina Nugent

The Yates Network

gina@theyatesnetwork.com